ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

• Main Authors: Hymowitz, Sarah G., Jin, Sha, Khaw, Seong Lin, Kovar, Peter J., Lam, Lloyd T., Lee, Jackie, Maecker, Heather L., Marsh, Kennan C., Mason, Kylie D., Mitten, Michael J., Sampath, Deepak, Nimmer, Paul M., Oleksijew, Anatol, Park, Chang H., Park, Cheol-Min, Phillips, Darren C., Roberts, Andrew W., Seymour, John F., Smith, Morey L., Sullivan, Gerard M., Tahir, Stephen K., Wendt, Michael D., Xiao, Yu, Xue, John C., Zhang, Haichao, Humerickhouse, Rod A., Rosenberg, Saul H., Elmore, Steven W., Tse, Chris, Souers, Andrew J., Leverson, Joel D., Boghaert, Erwin R., Ackler, Scott L., Catron, Nathaniel D., Chen, Jun, Dayton, Brian D., Ding, Hong, Enschede, Sari H., Fairbrother, Wayne J., Huang, David C. S.
• Other Authors: School of Physical and Mathematical Sciences
• Format: Article
• Language: English
• Published: 2013
• Subjects: DRNTU::Science::Chemistry::Biochemistry
• Online Access: https://hdl.handle.net/10356/107357; http://hdl.handle.net/10220/18024; http://dx.doi.org/10.1038/nm.3048
• Institution: Nanyang Technological University

Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of dir...